查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1628124

心臟闭合装置市场机会、成长驱动因素、产业趋势分析与预测 2025 - 2034 年

Heart Closure Devices Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025 - 2034
出版日期: | 出版商: Global Market Insights Inc. | 英文 130 Pages | 商品交期: 2-3个工作天内

价格
简介目录

全球心臟闭合装置市场到2024 年价值40 亿美元，预计2025 年至2034 年将以15.9% 的复合年增长率强劲增长。的转变，以及改善报销政策等因素。

心血管疾病（CVD）仍然是全球主要的健康问题，每年导致数百万人死亡。人口老化、生活方式相关风​​险因素的增加以及久坐的生活方式推动了对心臟闭合装置的需求。这些设备对于有效治疗心臟缺陷变得至关重要，并且由于其微创性质而被视为许多患者的理想解决方案。

心臟闭合装置的需求因其提供传统手术侵入性较小的替代方案的能力而受到推动。这些装置通常透过基于导管的手术插入，与传统的心臟直视手术相比，患者可以更快地康復，疼痛更少，住院时间更少。随着患者和医疗保健提供者越来越多地选择微创治疗，心臟闭合装置市场正在稳步成长。

市场范围
开始年份 2024年
预测年份 2025-2034
起始值 40 亿美元
预测值 177 亿美元
复合年增长率 15.9%

心臟闭合装置用于闭合异常的心臟开口，特别是房间隔缺损和室间隔缺损，这是先天性疾病。这些缺陷会导致心室之间出现意外的血流。从产品类型来看，市场分为左心耳（LAA）封堵器、房间隔缺损（ASD）封堵器、室间隔缺损（VSD）封堵器、卵圆孔未闭（PFO）封堵器等类别，LAA 设备因其众多优势而引领市场。

左心耳封堵器在降低中风风险方面特别有效，并提供了长期抗凝血治疗的替代方案，长期抗凝血治疗可能会导致併发症。这些设备因其低併发症率、更快的恢復速度和更少的住院时间而越来越受到青睐，从而导致更高的采用率。科技的进步和意识的提高也推动了左心耳设备的使用不断增加。

在材料方面，基于镍钛诺的心臟闭合装置由于其超弹性和优异的生物相容性预计将引领市场成长。这些装置被压缩到导管中，用于微创手术，并且在心臟内的动态力下表现良好，确保患者的长期安全。对可靠心血管解决方案不断增长的需求正在推动对这些设备的需求，预计到 2034 年市场规模将超过 92 亿美元。

经导管输送方法比传统手术侵入性更小，是心臟闭合装置市场的另一个关键成长动力。透过经导管手术，患者的併发症更少，恢復时间更快，使其成为医疗保健提供者和患者的普遍选择。随着经导管技术的不断改进，这些设备的市场份额预计将大幅增长。

就最终用途而言，医院凭藉其先进的设施和处理复杂心臟闭合手术的专业知识而占据市场主导地位。熟练的医疗专业人员的存在确保患者获得最高标准的护理，进一步巩固医院的市场领导地位。

北美引领全球心臟闭合设备市场，预计2025 年至2034 年复合年增长率为14.3%。领域的主导地位设备市场。

目录

第 1 章：方法与范围

第 2 章：执行摘要

第 3 章：产业洞察

  • 产业生态系统分析
  • 产业影响力
    • 成长动力
      • 心血管疾病盛行率不断上升
      • 技术进步
      • 对微创手术的偏好不断上升
      • 优惠报销政策
    • 产业陷阱与挑战
      • 严格的监理政策
      • 潜在的併发症和不良事件
  • 成长潜力分析
  • 监管环境
  • 报销场景
  • 2023 年定价分析
  • 技术景观
  • 未来市场趋势
  • 差距分析
  • 波特的分析
  • PESTEL分析

第 4 章：竞争格局

  • 介绍
  • 公司矩阵分析
  • 主要市场参与者的竞争分析
  • 竞争定位矩阵
  • 战略仪表板

第 5 章：市场估计与预测：按产品分类，2021 - 2034 年

  • 主要趋势
  • 心房中隔缺损 (ASD) 封堵器
  • 室间隔缺损 (VSD) 封堵器
  • 卵圆孔未闭 (PFO) 闭合装置
  • 左心耳 (LAA) 封堵器
  • 其他产品

第 6 章：市场估计与预测：按材料划分，2021 - 2034 年

  • 主要趋势
  • 基于镍钛诺的设备
  • 不銹钢装置
  • 其他材料

第 7 章：市场估计与预测：按交付方式，2021 年至 2034 年

  • 主要趋势
  • 经导管输送
  • 手术分娩

第 8 章：市场估计与预测：按最终用途，2021 - 2034 年

  • 主要趋势
  • 医院
  • 门诊手术中心 (ASC)
  • 心导管实验室
  • 其他最终用途

第 9 章：市场估计与预测：按地区划分，2021 - 2034 年

  • 主要趋势
  • 北美洲
    • 我们
    • 加拿大
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 西班牙
    • 义大利
    • 荷兰
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 澳洲
    • 韩国
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿联酋

第 10 章：公司简介

  • Abbott Laboratories
  • AtriCure
  • Biosense Webster
  • Boston Scientific Corporation
  • Cardia
  • Heartstitch
  • Lepu Medical Technology (Beijing)Co., Ltd.
  • LifeTech Scientific Corporation
  • Medtronic
  • Occlutech
  • SentreHEART
  • Starway Medical Technology
  • WL Gore & Associates
简介目录
Product Code: 6140

The Global Heart Closure Devices Market, valued at USD 4 billion in 2024, is expected to grow at a robust CAGR of 15.9% from 2025 to 2034. This growth can be attributed to the rising prevalence of cardiovascular diseases, a shift towards minimally invasive procedures, and improved reimbursement policies, among other factors.

Cardiovascular diseases (CVDs) remain a leading global health issue, contributing to millions of deaths annually. The aging population, increasing lifestyle-related risk factors, and sedentary living have propelled the demand for heart closure devices. These devices are becoming essential in treating heart defects effectively and are seen as an ideal solution for many patients due to their minimally invasive nature.

The demand for heart closure devices is fueled by their ability to offer a less invasive alternative to traditional surgeries. These devices are typically inserted via catheter-based procedures and allow patients to recover faster with less pain and fewer hospital stays compared to conventional open-heart surgeries. As patients and healthcare providers increasingly opt for minimally invasive treatments, the heart closure devices market is growing steadily.

Market Scope
Start Year2024
Forecast Year2025-2034
Start Value$4 Billion
Forecast Value$17.7 Billion
CAGR15.9%

Heart closure devices are used to close abnormal heart openings, particularly atrial and ventricular septal defects, which are congenital conditions. These defects cause unintended blood flow between the heart's chambers. In terms of product type, the market is divided into categories such as left atrial appendage (LAA) closure devices, atrial septal defect (ASD) closure devices, ventricular septal defect (VSD) closure devices, and patent foramen ovale (PFO) closure devices, with LAA devices leading the market due to their numerous benefits.

LAA closure devices are particularly effective in reducing stroke risk and offer an alternative to long-term anticoagulant therapy, which can cause complications. These devices are increasingly preferred for their low complication rates, faster recovery, and reduced hospital stays, leading to a higher adoption rate. Technological advances and increased awareness are also driving the growing use of LAA devices.

In terms of material, nitinol-based heart closure devices are expected to lead market growth, owing to their superelasticity and excellent biocompatibility. These devices are compressed into catheters for less invasive procedures and perform well under the dynamic forces within the heart, ensuring long-term patient safety. The growing need for reliable cardiovascular solutions is driving the demand for these devices, with the market projected to reach over USD 9.2 billion by 2034.

The transcatheter delivery method, which is less invasive than traditional surgery, is another key growth driver in the heart closure devices market. With transcatheter procedures, patients experience fewer complications and a faster recovery time, making it a popular choice among both healthcare providers and patients. As transcatheter technologies continue to improve, the market share for these devices is expected to grow significantly.

In terms of end-use, hospitals dominate the market due to their advanced facilities and expertise in handling complex heart closure procedures. The presence of skilled medical professionals ensures that patients receive the highest standard of care, further reinforcing hospitals' market leadership.

North America leads the global market for heart closure devices, with a projected CAGR of 14.3% from 2025 to 2034. The region's early adoption of innovative technologies, coupled with favorable reimbursement policies and substantial investments in research, further supports its dominance in the heart closure devices market.

Table of Contents

Chapter 1 Methodology and Scope

  • 1.1 Market scope and definitions
  • 1.2 Research design
    • 1.2.1 Research approach
    • 1.2.2 Data collection methods
  • 1.3 Base estimates and calculations
    • 1.3.1 Base year calculation
    • 1.3.2 Key trends for market estimation
  • 1.4 Forecast model
  • 1.5 Primary research and validation
    • 1.5.1 Primary sources
    • 1.5.2 Data mining sources

Chapter 2 Executive Summary

  • 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Growing prevalence of cardiovascular diseases
      • 3.2.1.2 Technological advancements
      • 3.2.1.3 Rising preference for minimally invasive procedures
      • 3.2.1.4 Favorable reimbursement policies
    • 3.2.2 Industry pitfalls and challenges
      • 3.2.2.1 Stringent regulatory policies
      • 3.2.2.2 Potential complications and adverse events
  • 3.3 Growth potential analysis
  • 3.4 Regulatory landscape
  • 3.5 Reimbursement scenario
  • 3.6 Pricing analysis, 2023
  • 3.7 Technology landscape
  • 3.8 Future market trends
  • 3.9 Gap analysis
  • 3.10 Porter's analysis
  • 3.11 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

  • 4.1 Introduction
  • 4.2 Company matrix analysis
  • 4.3 Competitive analysis of major market players
  • 4.4 Competitive positioning matrix
  • 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Product, 2021 - 2034 ($ Mn, Units)

  • 5.1 Key trends
  • 5.2 Atrial Septal Defect (ASD) Closure devices
  • 5.3 Ventricular Septal Defect (VSD) Closure devices
  • 5.4 Patent Foramen Ovale (PFO) Closure devices
  • 5.5 Left Atrial Appendage (LAA) Closure devices
  • 5.6 Other products

Chapter 6 Market Estimates and Forecast, By Material, 2021 - 2034 ($ Mn)

  • 6.1 Key trends
  • 6.2 Nitinol-based devices
  • 6.3 Stainless steel devices
  • 6.4 Other materials

Chapter 7 Market Estimates and Forecast, By Mode of Delivery, 2021 - 2034 ($ Mn)

  • 7.1 Key trends
  • 7.2 Transcatheter delivery
  • 7.3 Surgical delivery

Chapter 8 Market Estimates and Forecast, By End Use, 2021 - 2034 ($ Mn)

  • 8.1 Key trends
  • 8.2 Hospitals
  • 8.3 Ambulatory Surgical Centers (ASCs)
  • 8.4 Cardiac catheterization laboratories
  • 8.5 Other end use

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2034 ($ Mn, Units)

  • 9.1 Key trends
  • 9.2 North America
    • 9.2.1 U.S.
    • 9.2.2 Canada
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 France
    • 9.3.4 Spain
    • 9.3.5 Italy
    • 9.3.6 Netherlands
  • 9.4 Asia Pacific
    • 9.4.1 China
    • 9.4.2 Japan
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 South Korea
  • 9.5 Latin America
    • 9.5.1 Brazil
    • 9.5.2 Mexico
    • 9.5.3 Argentina
  • 9.6 Middle East and Africa
    • 9.6.1 South Africa
    • 9.6.2 Saudi Arabia
    • 9.6.3 UAE

Chapter 10 Company Profiles

  • 10.1 Abbott Laboratories
  • 10.2 AtriCure
  • 10.3 Biosense Webster
  • 10.4 Boston Scientific Corporation
  • 10.5 Cardia
  • 10.6 Heartstitch
  • 10.7 Lepu Medical Technology (Beijing)Co., Ltd.
  • 10.8 LifeTech Scientific Corporation
  • 10.9 Medtronic
  • 10.10 Occlutech
  • 10.11 SentreHEART
  • 10.12 Starway Medical Technology
  • 10.13 W. L. Gore & Associates